Accolade, Inc. (NASDAQ:ACCD – Get Free Report) was the recipient of a significant decline in short interest in the month of January. As of January 31st, there was short interest totalling 2,830,000 shares, a decline of 15.0% from the January 15th total of 3,330,000 shares. Based on an average daily volume of 2,010,000 shares, the days-to-cover ratio is currently 1.4 days.
Insiders Place Their Bets
In other Accolade news, CEO Rajeev Singh sold 13,357 shares of the firm’s stock in a transaction dated Tuesday, December 3rd. The shares were sold at an average price of $3.60, for a total value of $48,085.20. Following the transaction, the chief executive officer now owns 814,316 shares of the company’s stock, valued at $2,931,537.60. This trade represents a 1.61 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Insiders sold a total of 41,127 shares of company stock valued at $164,674 over the last 90 days. 8.20% of the stock is owned by company insiders.
Institutional Trading of Accolade
Several institutional investors and hedge funds have recently added to or reduced their stakes in ACCD. Whetstone Capital Advisors LLC bought a new position in shares of Accolade in the third quarter valued at $3,842,000. Johnson Financial Group LLC acquired a new position in shares of Accolade in the 3rd quarter worth $1,642,000. Nisa Investment Advisors LLC raised its position in shares of Accolade by 15,113.1% during the fourth quarter. Nisa Investment Advisors LLC now owns 55,680 shares of the company’s stock worth $190,000 after purchasing an additional 55,314 shares during the period. Point72 Asset Management L.P. purchased a new stake in shares of Accolade during the third quarter valued at $2,378,000. Finally, Barclays PLC boosted its position in shares of Accolade by 164.4% in the 3rd quarter. Barclays PLC now owns 139,901 shares of the company’s stock valued at $539,000 after purchasing an additional 86,981 shares during the period. 84.99% of the stock is owned by institutional investors and hedge funds.
Wall Street Analyst Weigh In
Read Our Latest Research Report on ACCD
Accolade Price Performance
ACCD opened at $6.90 on Monday. The company has a debt-to-equity ratio of 0.67, a quick ratio of 2.63 and a current ratio of 2.63. The company has a market capitalization of $562.94 million, a PE ratio of -3.07 and a beta of 2.20. The stock’s fifty day moving average is $5.38 and its 200-day moving average is $4.35. Accolade has a one year low of $3.08 and a one year high of $13.47.
Accolade (NASDAQ:ACCD – Get Free Report) last issued its quarterly earnings results on Friday, January 10th. The company reported ($0.30) EPS for the quarter, topping the consensus estimate of ($0.31) by $0.01. Accolade had a negative net margin of 40.36% and a negative return on equity of 20.74%. On average, equities analysts predict that Accolade will post -1.2 EPS for the current fiscal year.
Accolade Company Profile
Accolade, Inc, together with its subsidiaries, engages in the development and provision of personalized and technology-enabled solutions that help people to understand, navigate, and utilize the healthcare system and their workplace benefits in the United States. The company offers a platform with cloud-based intelligent technology and multimodal support from a team of advocates and clinicians, including registered nurses, physician medical directors, pharmacists, behavioral health specialists, women’s health specialists, case management specialists, expert medical opinion providers, and primary care physicians.
Recommended Stories
- Five stocks we like better than Accolade
- The 3 Best Retail Stocks to Shop for in August
- Symbotic Shares Down 37%—Is It Time for Bravery or Caution?
- The How And Why of Investing in Oil Stocks
- High-Yield Healthcare: 3 Stocks With Strong Dividends
- Earnings Per Share Calculator: How to Calculate EPS
- Beyond the Bargain Bin: 3 Stocks Leading Discount Retail
Receive News & Ratings for Accolade Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accolade and related companies with MarketBeat.com's FREE daily email newsletter.